Publications by authors named "Dharana Satsangi"

Glioblastoma multiforme (GBM) is one of the most common and aggressive type of malignant glioma with an average survival time of 12-18 mo. Despite the utilization of extensive surgical resections using cutting-edge neuroimaging, and advanced chemotherapy and radiotherapy, the prognosis remains unfavorable. The heterogeneity of GBM and the presence of the blood-brain barrier further complicate the therapeutic process.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the genetic basis of neurodevelopmental disorders (NDDs) in a diverse ethnic group with high consanguinity, focusing on 576 individuals to reveal significant genetic insights.
  • - Different sequencing methods were used to diagnose genetic causes, with a notable increase in diagnostic rates for children of consanguineous parents; combined CMA and exome sequencing yielded a 37.13% diagnostic rate.
  • - Key findings include the discovery of novel genetic variants related to NDDs, the identification of an association between G6PD variants and NDDs, and hints at the influence of ancient genetic drift in this Bangladeshi population.
View Article and Find Full Text PDF

Generation of human induced pluripotent stem cells (iPSCs) through reprogramming was a transformational change in the field of regenerative medicine that led to new possibilities for drug discovery and cell replacement therapy. Several protocols have been established to differentiate hiPSCs into neuronal lineages. However, low differentiation efficiency is one of the major drawbacks of these approaches.

View Article and Find Full Text PDF

Immune checkpoint blockade is the exciting breakthrough in cancer, but how immune checkpoints are activated is unknown. We have earlier reported that cell-free chromatin particles (cfChPs) that circulate in blood of cancer patients, or those that are released locally from dying cancer cells, are readily internalized by healthy cells with biological consequences. Here we report that treatment of human lymphocytes with cfChPs isolated from sera of cancer patients led to marked activation of the immune checkpoints PD-1, CTLA-4, LAG-3, NKG2A, and TIM-3.

View Article and Find Full Text PDF